CN111518175A - Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 - Google Patents
Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 Download PDFInfo
- Publication number
- CN111518175A CN111518175A CN202010392553.1A CN202010392553A CN111518175A CN 111518175 A CN111518175 A CN 111518175A CN 202010392553 A CN202010392553 A CN 202010392553A CN 111518175 A CN111518175 A CN 111518175A
- Authority
- CN
- China
- Prior art keywords
- associated virus
- cells
- recombinant adeno
- sequence
- cov
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (10)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010392553.1A CN111518175B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
CN202110019765.XA CN112695057B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
PCT/CN2020/127311 WO2021227401A1 (zh) | 2020-05-11 | 2020-11-07 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
EP20891416.8A EP4105228A4 (en) | 2020-05-11 | 2020-11-07 | ANTIGENIC POLYPEPTIDE OF SARS-COV-2, RECOMBINANT ADENO-ASSOCIATED VIRUS THEREOF, AND USE IN VACCINE PREPARATION |
US17/327,784 US20210346493A1 (en) | 2020-05-11 | 2021-05-24 | SARS-COV-2 Antigen Polypeptide, Recombinant Adeno-Associated Virus Expressing the Polypeptide, and Vaccine Containing the Virus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010392553.1A CN111518175B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110019765.XA Division CN112695057B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111518175A true CN111518175A (zh) | 2020-08-11 |
CN111518175B CN111518175B (zh) | 2021-02-26 |
Family
ID=71908796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010392553.1A Active CN111518175B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
CN202110019765.XA Active CN112695057B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110019765.XA Active CN112695057B (zh) | 2020-05-11 | 2020-05-11 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (2) | CN111518175B (zh) |
WO (1) | WO2021227401A1 (zh) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111939250A (zh) * | 2020-08-17 | 2020-11-17 | 郑州大学 | 一种预防covid-19的新型疫苗及其制备方法 |
CN111996216A (zh) * | 2020-09-01 | 2020-11-27 | 中国科学技术大学 | 腺相关病毒介导的新型冠状病毒抗体诱导物及疫苗组合物 |
CN112048005A (zh) * | 2020-09-04 | 2020-12-08 | 江苏省中国科学院植物研究所 | 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物 |
CN112251413A (zh) * | 2020-10-15 | 2021-01-22 | 北京鼎成肽源生物技术有限公司 | 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用 |
CN112359063A (zh) * | 2020-11-04 | 2021-02-12 | 安徽环球基因科技有限公司 | 新冠重组rbd蛋白在昆虫细胞中的生产方法 |
CN112386684A (zh) * | 2020-11-12 | 2021-02-23 | 佛山昭泰创新生物科技有限公司 | 一种covid-19疫苗及其制备方法和应用 |
CN112618707A (zh) * | 2020-10-15 | 2021-04-09 | 广州达博生物制品有限公司 | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 |
CN112710845A (zh) * | 2020-12-16 | 2021-04-27 | 北京热景生物技术股份有限公司 | 用于检测新冠状病毒中和抗体的试剂盒及检测方法 |
CN112710844A (zh) * | 2020-12-16 | 2021-04-27 | 北京开景基因技术有限公司 | 用于检测新型冠状病毒中和抗体的半定量试剂盒及方法 |
CN112921007A (zh) * | 2021-02-05 | 2021-06-08 | 华中农业大学 | 用于预防猫感染新冠病毒的重组腺相关病毒及其构建方法和应用 |
US20210190797A1 (en) * | 2020-02-19 | 2021-06-24 | Euroimmun Medizinische Labordiagnostika Ag | Methods and reagents for diagnosis of SARS-CoV-2 infection |
CN113024640A (zh) * | 2020-12-28 | 2021-06-25 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种基于新冠病毒rbd与ace2受体结合结构域筛选的表位肽抗原检测中和抗体试剂盒 |
WO2021227401A1 (zh) * | 2020-05-11 | 2021-11-18 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
CN114480442A (zh) * | 2020-10-27 | 2022-05-13 | 深圳吉诺因生物科技有限公司 | 一种mRNA及包含其的新型冠状病毒mRNA疫苗 |
CN114560931A (zh) * | 2022-04-27 | 2022-05-31 | 清华大学 | 抗SARS-CoV-2的中和抗体及其应用 |
WO2022171904A1 (en) | 2021-02-15 | 2022-08-18 | Livingmed Biotech S.R.L. | Genetically modified clostridium strains expressing recombinant antigens and uses thereof |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
CN115340998A (zh) * | 2021-05-14 | 2022-11-15 | 上海科技大学 | 一种重组病毒载体、包含其的重组病毒、新冠病毒疫苗及其应用 |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
EP4185323A4 (en) * | 2020-08-28 | 2024-08-21 | Biocad Joint Stock Co | AAV5 VACCINE AGAINST SARS-CoV-2 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111778264B (zh) * | 2020-07-14 | 2021-06-29 | 广州佰芮慷生物科技有限公司 | 基于新型腺病毒载体Sad23L和/或Ad49L的新型冠状病毒肺炎疫苗 |
CN113999293B (zh) * | 2021-12-30 | 2022-04-26 | 北京赛尔富森生物科技有限公司 | 一种特异性结合新型冠状病毒s蛋白的抗体及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1570115A (zh) * | 2003-07-16 | 2005-01-26 | 陈克勤 | 优化的sars冠状病毒刺突蛋白基因 |
US20060240515A1 (en) * | 2003-07-21 | 2006-10-26 | Dimitrov Dimiter S | Soluble fragments of the SARS-CoV spike glycoprotein |
CN101007168B (zh) * | 2006-01-23 | 2010-06-09 | 北京大学 | 一种sars疫苗及其制备方法 |
CN101182548B (zh) * | 2007-12-07 | 2010-12-08 | 北京工业大学 | Hpv16的1型重组腺相关病毒疫苗及其制备方法 |
CN104292338B (zh) * | 2013-07-18 | 2017-02-15 | 特菲(天津)生物医药科技有限公司 | 含sars病毒n抗原的重组蛋白及展示n蛋白的杆状病毒 |
CN104292339A (zh) * | 2013-07-18 | 2015-01-21 | 特菲(天津)生物医药科技有限公司 | 含sars病毒rbd抗原的重组蛋白及展示rbd蛋白的杆状病毒 |
CA3012699C (en) | 2016-04-21 | 2023-11-21 | Virovek, Inc | Aav production in insect cells, methods and compositions therefor |
CN110616198B (zh) * | 2018-06-19 | 2021-02-19 | 清华大学 | 一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗 |
CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
CN110974950B (zh) * | 2020-03-05 | 2020-08-07 | 广州恩宝生物医药科技有限公司 | 一种用于预防SARS-CoV-2感染的腺病毒载体疫苗 |
CN111024954A (zh) * | 2020-03-09 | 2020-04-17 | 深圳市易瑞生物技术股份有限公司 | 联合检测covid-19抗原和抗体的胶体金免疫层析装置及其使用法 |
CN111088283B (zh) * | 2020-03-20 | 2020-06-23 | 苏州奥特铭医药科技有限公司 | mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗 |
CN111474365B (zh) * | 2020-03-27 | 2021-09-17 | 北京大学 | 一种生物传感器及制备方法和病毒检测系统及方法 |
CN111518175B (zh) * | 2020-05-11 | 2021-02-26 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
-
2020
- 2020-05-11 CN CN202010392553.1A patent/CN111518175B/zh active Active
- 2020-05-11 CN CN202110019765.XA patent/CN112695057B/zh active Active
- 2020-11-07 WO PCT/CN2020/127311 patent/WO2021227401A1/zh unknown
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11964011B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11471525B2 (en) | 2020-02-04 | 2022-10-18 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US11964012B2 (en) | 2020-02-04 | 2024-04-23 | CureVac SE | Coronavirus vaccine |
US11596686B2 (en) | 2020-02-04 | 2023-03-07 | CureVac SE | Coronavirus vaccine |
US20210190797A1 (en) * | 2020-02-19 | 2021-06-24 | Euroimmun Medizinische Labordiagnostika Ag | Methods and reagents for diagnosis of SARS-CoV-2 infection |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
WO2021227401A1 (zh) * | 2020-05-11 | 2021-11-18 | 广东珩达生物医药科技有限公司 | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 |
CN111939250A (zh) * | 2020-08-17 | 2020-11-17 | 郑州大学 | 一种预防covid-19的新型疫苗及其制备方法 |
CN111939250B (zh) * | 2020-08-17 | 2022-07-29 | 郑州大学 | 一种预防covid-19的疫苗及其制备方法 |
EP4185323A4 (en) * | 2020-08-28 | 2024-08-21 | Biocad Joint Stock Co | AAV5 VACCINE AGAINST SARS-CoV-2 |
CN111996216B (zh) * | 2020-09-01 | 2022-09-09 | 中国科学技术大学 | 腺相关病毒介导的新型冠状病毒抗体诱导物及疫苗组合物 |
CN111996216A (zh) * | 2020-09-01 | 2020-11-27 | 中国科学技术大学 | 腺相关病毒介导的新型冠状病毒抗体诱导物及疫苗组合物 |
CN112048005A (zh) * | 2020-09-04 | 2020-12-08 | 江苏省中国科学院植物研究所 | 新型冠状病毒s蛋白片段多倍体及其制备方法、检测试剂盒、疫苗及药物 |
CN112251413B (zh) * | 2020-10-15 | 2021-05-14 | 焦顺昌 | 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用 |
CN112618707A (zh) * | 2020-10-15 | 2021-04-09 | 广州达博生物制品有限公司 | 一种SARS-CoV-2冠状病毒疫苗及其制备方法 |
CN112251413A (zh) * | 2020-10-15 | 2021-01-22 | 北京鼎成肽源生物技术有限公司 | 一种跨膜表达新型冠状病毒抗原的细胞的制备方法、细胞和应用 |
CN114480442A (zh) * | 2020-10-27 | 2022-05-13 | 深圳吉诺因生物科技有限公司 | 一种mRNA及包含其的新型冠状病毒mRNA疫苗 |
CN112359063A (zh) * | 2020-11-04 | 2021-02-12 | 安徽环球基因科技有限公司 | 新冠重组rbd蛋白在昆虫细胞中的生产方法 |
CN112386684B (zh) * | 2020-11-12 | 2023-12-05 | 广东昭泰细胞生物科技有限公司 | 一种covid-19疫苗及其制备方法和应用 |
CN112386684A (zh) * | 2020-11-12 | 2021-02-23 | 佛山昭泰创新生物科技有限公司 | 一种covid-19疫苗及其制备方法和应用 |
CN112710844A (zh) * | 2020-12-16 | 2021-04-27 | 北京开景基因技术有限公司 | 用于检测新型冠状病毒中和抗体的半定量试剂盒及方法 |
CN112710844B (zh) * | 2020-12-16 | 2023-07-07 | 北京开景基因技术有限公司 | 用于检测新型冠状病毒中和抗体的半定量试剂盒及方法 |
CN112710845B (zh) * | 2020-12-16 | 2023-07-07 | 北京热景生物技术股份有限公司 | 用于检测新冠状病毒中和抗体的试剂盒及检测方法 |
CN112710845A (zh) * | 2020-12-16 | 2021-04-27 | 北京热景生物技术股份有限公司 | 用于检测新冠状病毒中和抗体的试剂盒及检测方法 |
US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
CN113024640A (zh) * | 2020-12-28 | 2021-06-25 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种基于新冠病毒rbd与ace2受体结合结构域筛选的表位肽抗原检测中和抗体试剂盒 |
CN112921007A (zh) * | 2021-02-05 | 2021-06-08 | 华中农业大学 | 用于预防猫感染新冠病毒的重组腺相关病毒及其构建方法和应用 |
WO2022171904A1 (en) | 2021-02-15 | 2022-08-18 | Livingmed Biotech S.R.L. | Genetically modified clostridium strains expressing recombinant antigens and uses thereof |
CN115340998A (zh) * | 2021-05-14 | 2022-11-15 | 上海科技大学 | 一种重组病毒载体、包含其的重组病毒、新冠病毒疫苗及其应用 |
CN115340998B (zh) * | 2021-05-14 | 2023-12-01 | 上海科技大学 | 一种重组病毒载体、包含其的重组病毒、新冠病毒疫苗及其应用 |
CN114560931A (zh) * | 2022-04-27 | 2022-05-31 | 清华大学 | 抗SARS-CoV-2的中和抗体及其应用 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN112695057A (zh) | 2021-04-23 |
CN111518175B (zh) | 2021-02-26 |
CN112695057B (zh) | 2022-04-26 |
WO2021227401A1 (zh) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112695057B (zh) | Sars-cov-2抗原多肽及其重组腺相关病毒和在制备疫苗中的应用 | |
US10793861B2 (en) | Products and methods for treatment of familial amyotrophic lateral sclerosis | |
CN100571775C (zh) | 禽流感病毒标记疫苗及其制备方法和应用 | |
AU2016302335A1 (en) | GLP-1 and use thereof in compositions for treating metabolic diseases | |
CN108137664B (zh) | 用于治疗伴侣动物的aav-epo | |
US20030165520A1 (en) | Attenuated forms of bovine viral diarrhea virus | |
CN111575248A (zh) | 一种慢病毒、重组间充质干细胞及其构建方法和应用 | |
CN101985477A (zh) | 用于评价hcv ns3/4a丝氨酸蛋白酶抑制剂的融合蛋白及其应用 | |
KR102070763B1 (ko) | 도파민 신경세포 특이적 발현 제어 시스템 | |
CN106497960A (zh) | 一种用于大肠杆菌‑鸭疫里默氏杆菌的高效穿梭质粒 | |
CN112980819A (zh) | 视网膜色素变性动物模型的构建方法及其应用 | |
CN106520820B (zh) | 一种利用短芽胞杆菌制备脑钠肽前体抗原表位的方法 | |
CN114573694B (zh) | 一种抗IL13Rα2抗体及其制备方法和用途 | |
KR101973007B1 (ko) | 외래 단백질 발현 증가를 위한 재조합 전이 벡터 | |
US6423544B1 (en) | Compositions and methods for producing recombinant virions | |
KR20220111294A (ko) | 키메라 옵신 gpcr 단백질 | |
CN112759651B (zh) | 一种包含嵌合抗原受体修饰的t细胞及其应用 | |
CN110423776B (zh) | 表达重组凝血因子fix的载体及其构建方法和应用 | |
CN108866097A (zh) | 一种表达细粒棘球蚴eg95蛋白的重组羊痘病毒 | |
TW202302858A (zh) | 治療糖尿病之胰島素基因療法 | |
CN109295099A (zh) | Stub1重组过表达载体及其构建方法和用途 | |
CN108085325B (zh) | 一种抗草甘膦基因以及转基因抗草甘膦烟草的培育方法 | |
CN107090474A (zh) | 一种腹主动脉瘤疾病动物模型的制备方法 | |
CN112094823A (zh) | 一种新型的免疫检查点激活免疫共刺激的重组溶瘤痘苗病毒及其构建方法和应用 | |
CN101121752B (zh) | 以链亲和素为载体的短肽融合表达热诱导重组质粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200929 Address after: Room 105-70147, No.6 Baohua Road, Hengqin New District, Zhuhai City, Guangdong Province Applicant after: Guangdong keguanda Biomedical Technology Co., Ltd Address before: Room G304, G District, Guangzhou International Business Incubator, No.3, guanyue Road, Science City, Guangzhou high tech Industrial Development Zone, Guangdong Province Applicant before: GUANGZHOU PACKGENE BIOTECH. Co.,Ltd. Applicant before: Guangzhou University of Chinese Medicine (Guangzhou Institute of Chinese Medicine) |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201028 Address after: Room 801, building D, No. 98, Xiangxue 8th Road, Huangpu District, Guangzhou City, Guangdong Province 510000 Applicant after: Guangdong Hengda Biomedical Technology Co., Ltd Address before: Room 105-70147, No.6 Baohua Road, Hengqin New District, Zhuhai City, Guangdong Province Applicant before: Guangdong keguanda Biomedical Technology Co., Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220111 Address after: 511455 Room 403, 4th floor, building 31 (Building B), Caihui center, No. 1, Cuiying street, Nansha District, Guangzhou City, Guangdong Province Patentee after: Guangdong keguanda Pharmaceutical Technology Co.,Ltd. Address before: 510000 room 801, building D, 98 xiangxueba Road, Huangpu District, Guangzhou City, Guangdong Province Patentee before: Guangdong Hengda Biomedical Technology Co., Ltd |